Does the media refer more to ARQT or TBPH?

In the previous week, Arcutis Biotherapeutics had 3 more articles in the media than Theravance Biopharma. MarketBeat recorded 4 mentions for Arcutis Biotherapeutics and 1 mentions for Theravance Biopharma. Arcutis Biotherapeutics' average media sentiment score of 0.84 beat Theravance Biopharma's score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Theravance Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MBX or TBPH?

In the previous week, MBX Biosciences had 4 more articles in the media than Theravance Biopharma. MarketBeat recorded 5 mentions for MBX Biosciences and 1 mentions for Theravance Biopharma. MBX Biosciences' average media sentiment score of 1.25 beat Theravance Biopharma's score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Theravance Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TARS or TBPH?

In the previous week, Tarsus Pharmaceuticals had 1 more articles in the media than Theravance Biopharma. MarketBeat recorded 2 mentions for Tarsus Pharmaceuticals and 1 mentions for Theravance Biopharma. Tarsus Pharmaceuticals' average media sentiment score of 1.15 beat Theravance Biopharma's score of 0.00 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Theravance Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate TBPH or MOR?

Theravance Biopharma currently has a consensus target price of $19.40, indicating a potential upside of 14.05%. Given Theravance Biopharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Theravance Biopharma is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theravance Biopharma 0 Sell rating(s) 7 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.25 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to SUPN or TBPH?

In the previous week, Supernus Pharmaceuticals had 5 more articles in the media than Theravance Biopharma. MarketBeat recorded 6 mentions for Supernus Pharmaceuticals and 1 mentions for Theravance Biopharma. Supernus Pharmaceuticals' average media sentiment score of 1.10 beat Theravance Biopharma's score of 0.00 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Theravance Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Theravance Biopharma (TBPH) Competitors

$17.01 +0.06 (+0.35%)

As of 08/21/2026 04:00 PM Eastern

Compare

TBPH vs. ARQT, MBX, TARS, MOR, and SUPN

Should you buy Theravance Biopharma stock or one of its competitors? Theravance Biopharma's main competitors and comparable companies include Arcutis Biotherapeutics (ARQT), MBX Biosciences (MBX), Tarsus Pharmaceuticals (TARS), MorphoSys (MOR), and Supernus Pharmaceuticals (SUPN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Theravance Biopharma compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Theravance Biopharma (NASDAQ:TBPH) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

99.1% of Theravance Biopharma shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 7.7% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Theravance Biopharma has a net margin of 51.58% compared to Arcutis Biotherapeutics' net margin of 6.15%. Arcutis Biotherapeutics' return on equity of 15.05% beat Theravance Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Theravance Biopharma	51.58%	-0.77%	-0.46%

Arcutis Biotherapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

Arcutis Biotherapeutics presently has a consensus price target of $35.57, indicating a potential upside of 41.83%. Theravance Biopharma has a consensus price target of $19.40, indicating a potential upside of 14.05%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Arcutis Biotherapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Theravance Biopharma	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.25

In the previous week, Arcutis Biotherapeutics had 3 more articles in the media than Theravance Biopharma. MarketBeat recorded 4 mentions for Arcutis Biotherapeutics and 1 mentions for Theravance Biopharma. Arcutis Biotherapeutics' average media sentiment score of 0.84 beat Theravance Biopharma's score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Theravance Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Theravance Biopharma has lower revenue, but higher earnings than Arcutis Biotherapeutics. Theravance Biopharma is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.38	-$16.14M	$0.21	119.43
Theravance Biopharma	$104.31M	8.47	$105.89M	$1.01	16.84

Summary

Arcutis Biotherapeutics beats Theravance Biopharma on 11 of the 17 factors compared between the two stocks.

How does Theravance Biopharma compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Theravance Biopharma (NASDAQ:TBPH) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

MBX Biosciences currently has a consensus price target of $77.00, indicating a potential upside of 16.09%. Theravance Biopharma has a consensus price target of $19.40, indicating a potential upside of 14.05%. Given MBX Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe MBX Biosciences is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Theravance Biopharma	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.25

Theravance Biopharma has a net margin of 51.58% compared to MBX Biosciences' net margin of 0.00%. Theravance Biopharma's return on equity of -0.77% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.02%	-24.94%
Theravance Biopharma	51.58%	-0.77%	-0.46%

MBX Biosciences has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

99.1% of Theravance Biopharma shares are held by institutional investors. 31.1% of MBX Biosciences shares are held by insiders. Comparatively, 7.7% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Theravance Biopharma has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
Theravance Biopharma	$104.31M	8.47	$105.89M	$1.01	16.84

In the previous week, MBX Biosciences had 4 more articles in the media than Theravance Biopharma. MarketBeat recorded 5 mentions for MBX Biosciences and 1 mentions for Theravance Biopharma. MBX Biosciences' average media sentiment score of 1.25 beat Theravance Biopharma's score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Theravance Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Theravance Biopharma beats MBX Biosciences on 9 of the 15 factors compared between the two stocks.

How does Theravance Biopharma compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Theravance Biopharma (NASDAQ:TBPH) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 7.7% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Theravance Biopharma has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	7.07	-$66.42M	-$1.09	N/A
Theravance Biopharma	$104.31M	8.47	$105.89M	$1.01	16.84

In the previous week, Tarsus Pharmaceuticals had 1 more articles in the media than Theravance Biopharma. MarketBeat recorded 2 mentions for Tarsus Pharmaceuticals and 1 mentions for Theravance Biopharma. Tarsus Pharmaceuticals' average media sentiment score of 1.15 beat Theravance Biopharma's score of 0.00 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Theravance Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tarsus Pharmaceuticals has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

Tarsus Pharmaceuticals currently has a consensus price target of $90.50, suggesting a potential upside of 24.48%. Theravance Biopharma has a consensus price target of $19.40, suggesting a potential upside of 14.05%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Theravance Biopharma	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.25

Theravance Biopharma has a net margin of 51.58% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Theravance Biopharma's return on equity of -0.77% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Theravance Biopharma	51.58%	-0.77%	-0.46%

Summary

Tarsus Pharmaceuticals beats Theravance Biopharma on 9 of the 17 factors compared between the two stocks.

How does Theravance Biopharma compare to MorphoSys?

Theravance Biopharma (NASDAQ:TBPH) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Theravance Biopharma has a net margin of 51.58% compared to MorphoSys' net margin of -226.79%. Theravance Biopharma's return on equity of -0.77% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	51.58%	-0.77%	-0.46%
MorphoSys	-226.79%	-694.31%	-22.55%

Theravance Biopharma currently has a consensus target price of $19.40, indicating a potential upside of 14.05%. Given Theravance Biopharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Theravance Biopharma is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.25
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Theravance Biopharma has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$104.31M	8.47	$105.89M	$1.01	16.84
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

In the previous week, Theravance Biopharma had 1 more articles in the media than MorphoSys. MarketBeat recorded 1 mentions for Theravance Biopharma and 0 mentions for MorphoSys. Theravance Biopharma's average media sentiment score of 0.00 equaled MorphoSys'average media sentiment score.

Company	Overall Sentiment
Theravance Biopharma	Neutral
MorphoSys	Neutral

Theravance Biopharma has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 7.7% of Theravance Biopharma shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Theravance Biopharma beats MorphoSys on 12 of the 15 factors compared between the two stocks.

How does Theravance Biopharma compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Theravance Biopharma (NASDAQ:TBPH) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

Theravance Biopharma has a net margin of 51.58% compared to Supernus Pharmaceuticals' net margin of -13.23%. Supernus Pharmaceuticals' return on equity of 11.13% beat Theravance Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%
Theravance Biopharma	51.58%	-0.77%	-0.46%

Supernus Pharmaceuticals presently has a consensus price target of $62.83, suggesting a potential upside of 37.04%. Theravance Biopharma has a consensus price target of $19.40, suggesting a potential upside of 14.05%. Given Supernus Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Supernus Pharmaceuticals is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Theravance Biopharma	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.25

In the previous week, Supernus Pharmaceuticals had 5 more articles in the media than Theravance Biopharma. MarketBeat recorded 6 mentions for Supernus Pharmaceuticals and 1 mentions for Theravance Biopharma. Supernus Pharmaceuticals' average media sentiment score of 1.10 beat Theravance Biopharma's score of 0.00 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Theravance Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.1% of Theravance Biopharma shares are owned by institutional investors. 8.5% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 7.7% of Theravance Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Supernus Pharmaceuticals has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

Theravance Biopharma has lower revenue, but higher earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$830.44M	3.21	-$38.55M	-$1.92	N/A
Theravance Biopharma	$104.31M	8.47	$105.89M	$1.01	16.84

Summary

Supernus Pharmaceuticals beats Theravance Biopharma on 10 of the 16 factors compared between the two stocks.

Get Theravance Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TBPH vs. The Competition

Export

Metric	Theravance Biopharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$883.14M	$12.57B	$7.37B	$12.85B
Dividend Yield	N/A	2.61%	2.53%	11.08%
P/E Ratio	16.84	789.80	272.60	24.24
Price / Sales	8.47	764.50	618.96	99.78
Price / Cash	N/A	96.77	78.62	53.99
Price / Book	3.05	11.89	13.05	6.20
Net Income	$105.89M	$2.81B	$3.47B	$348.59M
7 Day Performance	0.24%	1.77%	2.09%	0.08%
1 Month Performance	0.89%	3.85%	6.64%	3.88%
1 Year Performance	22.29%	6.56%	25.02%	16.98%

Theravance Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TBPH Theravance Biopharma	2.1502 of 5 stars	$17.01 +0.4%	$19.40 +14.1%	+22.3%	$883.14M	$104.31M	16.84	110
ARQT Arcutis Biotherapeutics	4.0698 of 5 stars	$25.92 +1.2%	$35.57 +37.2%	+56.9%	$3.25B	$463.98M	123.22	150	Analyst Upgrade Insider Trade
MBX MBX Biosciences	2.9855 of 5 stars	$66.86 -2.0%	$75.63 +13.1%	N/A	$3.22B	N/A	N/A	N/A	News Coverage Positive News Analyst Forecast Gap Up
TARS Tarsus Pharmaceuticals	3.1849 of 5 stars	$70.51 -0.1%	$90.50 +28.4%	+27.0%	$3.09B	$606.33M	N/A	50	Positive News
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TBPH) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Theravance Biopharma (TBPH) Competitors

TBPH vs. ARQT, MBX, TARS, MOR, and SUPN

How does Theravance Biopharma compare to Arcutis Biotherapeutics?

Summary

How does Theravance Biopharma compare to MBX Biosciences?

Summary

How does Theravance Biopharma compare to Tarsus Pharmaceuticals?

Summary

How does Theravance Biopharma compare to MorphoSys?

Summary

How does Theravance Biopharma compare to Supernus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH vs. The Competition

Theravance Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Theravance Biopharma (TBPH) Competitors

TBPH vs. ARQT, MBX, TARS, MOR, and SUPN

How does Theravance Biopharma compare to Arcutis Biotherapeutics?

Do insiders & institutionals believe in ARQT or TBPH?

Is ARQT or TBPH more profitable?

Which has more volatility and risk, ARQT or TBPH?

Do analysts prefer ARQT or TBPH?

Does the media refer more to ARQT or TBPH?

Which has better valuation and earnings, ARQT or TBPH?

Summary

How does Theravance Biopharma compare to MBX Biosciences?

Do analysts prefer MBX or TBPH?

Is MBX or TBPH more profitable?

Which has more risk & volatility, MBX or TBPH?

Do institutionals and insiders believe in MBX or TBPH?

Which has higher earnings & valuation, MBX or TBPH?

Does the media refer more to MBX or TBPH?

Summary

How does Theravance Biopharma compare to Tarsus Pharmaceuticals?

Do institutionals & insiders have more ownership in TARS or TBPH?

Which has stronger earnings & valuation, TARS or TBPH?

Does the media prefer TARS or TBPH?

Which has more volatility and risk, TARS or TBPH?

Do analysts recommend TARS or TBPH?

Is TARS or TBPH more profitable?

Summary

How does Theravance Biopharma compare to MorphoSys?

Is TBPH or MOR more profitable?

Do analysts rate TBPH or MOR?

Which has better valuation & earnings, TBPH or MOR?

Does the media favor TBPH or MOR?

Which has more risk and volatility, TBPH or MOR?

Do institutionals & insiders hold more shares of TBPH or MOR?

Summary

How does Theravance Biopharma compare to Supernus Pharmaceuticals?

Is SUPN or TBPH more profitable?

Do analysts recommend SUPN or TBPH?

Does the media refer more to SUPN or TBPH?

Do institutionals and insiders have more ownership in SUPN or TBPH?

Which has more risk and volatility, SUPN or TBPH?

Which has stronger valuation and earnings, SUPN or TBPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH vs. The Competition

Theravance Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools